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Objectives: Clinical trials and observational studies have produced contradictory results regarding the
association of bloodpressure (BP) andmortality inpeople aged 80 years or older. Gait speed at usual pace has
been shown to moderate this association in a population of noninstitutionalized people aged 65 years or
older. The aims of this study were to investigate the association of BP with all-cause mortality in a repre-
sentative sampleofpeopleaged85yearsorolderand toassesswhethergait speedmoderates thisassociation.
Design, Setting, and Participants: A total of 806 participants in the population-based prospective Umeå
85þ/GERDA study aged 85, 90, and 95 years or older.
Measurements: Gait speed at usual pace was measured over 2.4 m. The main outcome was hazard ratios
(HRs) for all-cause mortality according to systolic and diastolic BP categories in the total sample and in
faster-walking (0.5 m/s, n ¼ 312) and slower-walking (<0.5 m/s, n ¼ 433) subcohorts; the latter also
included habitually nonwalking participants. Comprehensive adjustments were made for sociodemo-
graphic and clinical characteristics associated with death.
Results: Mean age and baseline systolic and diastolic BP were 89.6  4.6 years, 146.8  23.9 mm Hg, and
74.8  11.1 mm Hg, respectively. Most (n ¼ 561 [69%]) participants were women, 315 (39%) were care
facility residents, and 566 (70%) were prescribed BP-lowering drugs. Within 5 years, 490 (61%) partici-
pants died. In the total sample and slower-walking subcohort, systolic BP appeared to be inversely
associated with mortality, although not independent of adjustments. Among faster-walking participants,
mortality risk after adjustment was more than 2 times higher in those with systolic BP of 140 to 149 mm
Hg (HR ¼ 2.25, 95% conﬁdence interval [CI] ¼ 1.03e4.94) and 165 mm Hg or higher (HR ¼ 2.13, 95%
CI ¼ 1.01e4.49), compared with systolic BP of 126 to 139 mm Hg. Mortality risk was also independently
higher in faster-walking participants with diastolic BP higher than 80 mm Hg, compared with diastolic
BP of 75 to 80 mm Hg (HR ¼ 1.76, 95% CI ¼ 1.07e2.90).
Conclusion: The gait speed threshold of 0.5 m/s may be clinically useful for the distinction of very old
people with and without increased all-cause mortality risk due to elevated systolic and diastolic BP.
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and Long-Term Care Medicine. ThThe population of very old people (aged 85 years) is growing
rapidly, along with an increasing prevalence of hypertension.1,2 The
association between blood pressure (BP) and mortality is not entirely
understood in this population, including those with multimorbidity
and those living in residential care facilities. Results of population-
based studies3e10 have suggested that hypertension is not a risk
factor for death in very old individuals. Antihypertensive treatment has
been shown to have positive effects on cardiovascular morbidity in
a systematic review11 and a large meta-analysis12 of randomized
controlled trials, but neither study foundanyeffect on overallmortality
in people aged 80 years or older. However, the Hypertension in theis is an open access article under the CC BY-NC-ND license (http://creativecommons.
Eligible participants
(n = 1310)
Age Men Women Total
85 197 376 573
90 124 282 406
≥95 65 266 331
Total 386 924 1310
Excluded (n = 504)
Deceased before contact (n = 115)
Declined home visit (n = 347)
No blood pressure obtained (n = 42)
Included in total sample
(n = 806)
Age Men Women Total
85 120 228 348
90 87 173 260
≥95 38 160 198
Total 245 561 806
Excluded from gait speed cohorts (n = 61)
Walking test not performed due to:
Cognitive impairment (n = 17)
Motivation (n = 18)
Severe vision or hearing impairment (n = 3)
Recent fracture (n = 2)
Environmental limitation (n = 1)
Other (n = 2)
Reasons unknown (n = 18)
Included in gait speed 
cohorts (n = 745)
Age Men Women Total
85 113 221 334
90 77 156 233
≥95 37 141 178
Total 227 518 745
Alive after 5 years
(n = 316)
Alive after 5 years
(n = 304)
Deceased within 5 years
(n = 441)
Deceased within 5 years
(n = 490)
Fig. 1. Flow chart of study participation.
B. Weidung et al. / JAMDA 16 (2015) 208e214 209Very Elderly Trial (HYVET),13 the largest double-blind, placebo-
controlled trial to examine this issue, found that antihypertensive
therapy markedly reduced total mortality in people aged 80 years or
older. Because the level of comorbidity in theHYVETsamplewas low in
comparisonwith that of the general population of very old individuals,
the applicability of this study’s ﬁndings to the latter remains unclear.
Gait speed, measured over a short distance, is an integrative mea-
sure of health and functional abilities that has been shown to predict
adverse outcomes and mortality risk.14e17 Using gait speed to divide a
population of noninstitutionalized adults aged 65 years or older into
subcohorts, Odden et al18 found that hypertensionwas associatedwith
all-cause mortality only in participants whose usual pace was 0.8 m/s
or faster. In slower-walking participants, including those who were
physically unable to complete the walk, BP was not associated with
mortality. Gait speed thus appears to distinguish groups of older
people with and without increased mortality risk related to hyper-
tension. However, the mean age of participants in the study by Odden
et al18 was 74 years, and its results remain to be conﬁrmed in the very
old population. The cutoff value of 0.8 m/s for gait speed has beenwell
supported in the scientiﬁc literature for younger old populations, but a
lower threshold may be more suitable for very old, and generally
slower-walking, people.15
This study was conducted to investigate the association between
BP and mortality in a representative sample of very old people and to
assess whether gait speed at usual pace could moderate this
association.
Methods
Setting and Design
This study was based on data from the Umeå 85þ/GErontological
Regional DAtabase (GERDA) population-based cohort study by Umeå
University, Sweden. Half of inhabitants aged 85 years (selected from a
randomized starting point) and all of those aged 90 and 95 years or
older in 8 municipalities of northern Sweden and western Finland
were selected from national tax and population registers for partici-
pation in the Umeå 85þ/GERDA study. The objective of the study was
to increase knowledge of the living conditions of very old people, in-
crease quality of life, and provide data to support planning of future
eldercare. Data collection commenced in 2000, 2002, 2005, and 2007;
in 2005 itwas conducted in collaborationwithÅboAkademiUniversity
and the University of Vaasa, Finland. The study design has been
described in detail elsewhere.19 Eligible participants were invited by
mail to participate in the study and subsequently contacted by tele-
phone to obtain informed consent. For participants with cognitive
impairment, a close relative also provided oral consent, when appro-
priate. Trained assessors visited all participants at their homes or in-
stitutions to conduct standardized interviews and tests. Relatives and/
or health care professionals were interviewed when needed and the
medical records of all consenting participants were reviewed. The
Umeå 85þ/GERDA study has been approved by the Regional Ethical
ReviewBoard in Umeå (x99-326, x05-063M) and the Ethics Committee
of Vaasa Central Hospital (registration number 05-87).
Participants
Of 1310 eligible Umeå 85þ/GERDA study participants, 115 died
before contact and 347 declined home visits (Figure 1). All partici-
pants whose BP was measured (n ¼ 806; 67.4% participation rate)
were included in the present study. The 389 nonparticipants who
declined home visits or for whom no BP measurement was obtained
did not differ signiﬁcantly from participants in age (P ¼ .636) or sex
(P ¼ .136). For persons who participated in more than one round ofdata collection, the earliest dataset was used. Gait speed was assessed
in 609 participants, who were included in gait speed analyses and
subcohorts. Of 197 participants who were unable to complete the gait
speed test, 136 participants were included in a gait-speed subcohort
because they were considered to have habitual physical impairment
of gait function (habitually nonwalking), which may reﬂect mortality
risk in this population.15 Sixty-one of those who were unable to
complete the gait speed test were excluded from gait speed analyses
and subcohorts because of recent fracture preventing gait speed
assessment, failure to understand instructions, severe visual or
hearing impairment, environmental limitation, or other reasons not
related to a habitual physical impairment of gait function. In total, 745
participants were included in gait speed subcohorts.Measures
Dates of death were collected from death certiﬁcates, electronic
medical records, and population registers for the 5 years after the
date of study inclusion. Information on participants’ age, sex, living
conditions, education, and smoking status was collected during in-
terviews. BP was measured using a calibrated manual sphygmoma-
nometer and stethoscope with participants supine after 5 minutes of
B. Weidung et al. / JAMDA 16 (2015) 208e214210rest. In 51 participants, BP measurements were registered in a seated
position; in 11 cases, measurements were obtained from medical
records of recent health clinic visits because of missing values.
Systolic BP was classiﬁed in quintiles (125, 126e139, 140e149,
150e164, and 165 mm Hg) and diastolic BP was classiﬁed in quar-
tiles (<70, 70e74, 75e80, and >80 mm Hg) because its distribution
was narrower than that of systolic BP. Gait speed over a distance of
2.4 m20,21 was measured twice and a mean value was calculated.
When only one gait speed measurement was obtained, it was
included in the analysis. Starting from a standing still position, the
participants were instructed to walk past a mark on the ﬂoor at their
usual pace and were timed using a digital stopwatch. Walking aids
were permitted, but no personal assistance or support from nearby
structures was allowed. Gait speed was dichotomized to form 2 gait
speed subcohorts. Few (n ¼ 53) participants had gait speeds of
0.8 m/s or faster, preventing subcohort formation on this basis. An
alternative cutoff value of 0.5 m/s, which has been shown to distin-
guish between higher and lower mortality risk in very old in-
dividuals,15 was thus used to form a faster-walking (0.5 m/s) and
slower-walking (<0.5 m/s) subcohort; the latter also included
habitually nonwalking participants. Body mass index was calculated
by dividing weight (in kilograms) by the square of height (in meters).
The Mini-Mental State Examination (MMSE) was used to assess
cognition on a scale of 0 to 30, with higher scores indicating better
cognitive function.22 Dependency in activities of daily living (ADLs)
was assessed using the Barthel ADL Index on a scale of 0 to 20, with a
score of 20 indicating total independence in personal ADLs.23
Information on participants’ medical history and drug pre-
scriptions was collected during interviews and veriﬁed using medical
records. Diagnoses of dementia, depression, and angina pectoris were
based on previous diagnoses and current drug prescription. Assess-
ment scores also were applied to diagnose dementia and depression
according to Diagnostic and Statistical Manual of Mental Disorders,
Fourth edition, criteria.24 A specialist in geriatric medicine reviewed
and conﬁrmed all diagnoses. A covariate of all BP-lowering drugs was
deﬁned to include prescriptions of angiotensin-converting enzyme
(ACE) inhibitors, beta-blockers (excluding eye drops), calcium chan-
nel blockers, diuretics (except in patients with concurrent heart
failure), and other BP-lowering drugs, irrespective of indication.Statistical Analysis
Differences in 5-year mortality and gait speed subcohorts ac-
cording to sociodemographic and clinical characteristics were as-
sessed using Student t-test and Pearson c2 test. Differences in 5-year
mortality according to age (85, 90, and 95 years) and gait speed
groups (slower- and faster-walking, habitually nonwalking, and
excluded nonwalking) were examined using the Pearson c2 test.
Differences in mean gait speed, systolic BP, and diastolic BP according
to age and gait speed groups were assessed using 1-way analyses of
variance. Correlations were tested between all baseline covariates,
and the ADL score covariate was removed from the analyses due to
strong (r > 0.6) correlations with the care facility residency, MMSE
score, diagnosis of dementia, and gait speed covariates. The diagnosis
of dementia covariate was removed due to strong correlation with
MMSE score. The antidepressant prescription covariate was removed
to reduce the risk of an overlapping effect with the diagnosis of
depression covariate.
Associations between all-cause mortality and categorized systolic
and diastolic BP, respectively, were analyzed using Cox proportional
hazard regression models. In the total sample, model 1 was adjusted
for age and sex, andmodel 2 was adjusted for age, sex, and all baseline
variables from Table 1 associated with mortality at a signiﬁcance level
of P  .15 in univariate analyses. Proportionality of hazards was testedusing Schoenfeld residuals.25 Assumptions were not fulﬁlled for the
age and education covariates, which were adjusted for using time-
dependent variables in an extended Cox proportional hazard regres-
sion model. An interaction termwas entered in bothmodels to test for
any interaction effect between systolic BP and gait speed. The associ-
ation of BP with mortality also was analyzed in gait speed subcohorts.
To reduce the number of covariates used to examine gait speed sub-
cohorts, which were characterized by fewer events (deaths within
5 years),26 only variables from model 2 in the total sample that were
associated with mortality at a signiﬁcance level of P  .05 in multi-
variate analysis (age, age  follow-up time, sex, congestive heart fail-
ure, atrial ﬁbrillation,myocardial infarction, cancer, depression, angina
pectoris, body mass index, and MMSE score) were included in this
model. To control for the inﬂuence of early death, analyses using both
models were repeated with the exclusion of data from participants
who died in the ﬁrst year after data collection. Statistical analyses
were performed using SPSS statistics software (version 20.0; IBM
Corporation, Armonk, NY). All analyses were 2-tailed and P < .05 was
considered signiﬁcant.Results
Table 1 shows the baseline characteristics of the study population
with respect to survival status and gait speed subcohort. In the study
population (n¼ 806), themean agewas 89.6 years. A total of 490 (61%)
participants died within 5 years (mean, 3.34 years) after study inclu-
sion. Approximately two-thirds (n¼ 561) of participantswerewomen,
most (63%) of whom had gait speeds slower than 0.5 m/s (slower-
walking subcohort, also including habitually nonwalking participants).
The slower-walking subcohort included 3 times as many women as
men. Almost two-ﬁfths (39%) of study participants were living in a
residential care facility, and few (16%) of these participants were
assigned to the faster-walking subcohort. BP-lowering drugs were
prescribed to 70% of participants. ACE inhibitor and diuretic pre-
scriptions were signiﬁcantly more prevalent in the slower-walking
subcohort (20% and 54%, respectively) and among those who died
within 5 years of study inclusion (21% and 52%, respectively) than in
other groups. High age, care facility residency, living alone, congestive
heart failure, atrial ﬁbrillation, cerebrovascular disease, dementia, hip
fracture, depression, and angina pectoris also were signiﬁcantly more
prevalent among thosewho died within 5 years of study inclusion and
those in the slower-walking subcohort. Gait speed and BP were lower
among those who died within 5 years than among those who lived
(gait speed [mean standard deviation], 0.46 0.20 vs 0.58 0.21m/s,
P < .001; systolic BP, 142.7  23.9 vs 153.3  22.4 mm Hg, P < .001;
diastolic BP, 73.7  11.3 vs 76.5  10.4 mm Hg, P < .001).
Table 2 presents mean gait speed, BP, and survival status according
to age and gait speed groups. Gait speed and BP showed decreasing
trends with increasing age. BP also showed decreasing trends with
decreasing gait speed, while the proportion of deaths increased.
Hazard ratios (HRs) for death in the total sample and according to
gait speed subcohort are presented for systolic BP in Table 3 and
diastolic BP in eTable 1. Survival curves based on Cox proportional
hazard regression models are shown for systolic BP in Figure 2 and
diastolic BP in eFigure 1. In initial age- and sex-adjusted analysis of
the total sample (model 1), compared with systolic BP  125 mm Hg,
mortality risk decreased with increasing BP category (126e139 mm
Hg: HR 0.70, 95% conﬁdence interval [CI] 0.53e0.93; 140e149 mm
Hg: HR 0.63, 95% CI 0.48e0.83; 150e164 mm Hg: HR 0.59, 95% CI
0.45e0.76; 165 mm Hg: HR 0.50, 95% CI 0.38e0.66; Table 3,
Figure 2A). None of these associations was signiﬁcant in the fully
adjusted model for the total sample (model 2). For diastolic BP,
mortality risk was signiﬁcantly increased in the quartile of BP lower
than 70 mm Hg in model 1 (HR 1.42, 95% CI 1.11e1.81) and in the
Table 1
Baseline Sociodemographic and Clinical Characteristics of the Study Population
Characteristic 5-y Follow-up Status P Gait Speed Cohort P
Alive
(n ¼ 316)
Deceased
(n ¼ 490)
0.5 m/s
(n ¼ 312)
<0.5 m/s*
(n ¼ 433)
Age, y 87.6  3.4 90.9  4.7 <.001 87.9  3.8 90.6  4.8 <.001
Sex, female 228 (72) 333 (68) .206 192 (62) 326 (75) <.001
Care facility residency 48 (15) 267 (55) <.001 45 (14) 235 (54) <.001
Living alone, n ¼ 805 241 (76) 412 (84) .005 229 (74) 374 (86) <.001
Education <8 y, n ¼ 780 216 (69) 357 (77) .015 217 (70) 316 (75) .118
Current smoker, n ¼ 799 11 (4) 16 (3) .887 18 (6) 7 (2) .002
Former smoker, n ¼ 772 89 (29) 121 (26) .297 105 (36) 96 (23) <.001
Diagnoses and medical conditions
Diabetes 38 (12) 75 (15) .190 42 (14) 61 (14) .807
Congestive heart failure, n ¼ 805 48 (15) 190 (39) <.001 60 (19) 155 (36) <.001
Atrial ﬁbrillation 43 (14) 137 (28) <.001 51 (16) 111 (26) .002
MI in the previous year 5 (2) 18 (4) .082 9 (3) 12 (3) .927
Cerebrovascular disease 52 (17) 108 (22) .052 36 (12) 110 (25) <.001
Cancer previous 5 y 27 (9) 59 (12) .116 31 (10) 48 (11) .615
Dementia 41 (13) 236 (48) <.001 33 (11) 203 (47) <.001
Hip fracture 37 (12) 105 (21) <.001 28 (9) 96 (22) <.001
COPD 50 (16) 84 (17) .623 46 (15) 78 (18) .237
Depression, n ¼ 801 70 (22) 188 (39) <.001 61 (20) 172 (40) <.001
Rheumatic disorders 43 (14) 67 (14) .979 28 (9) 72 (17) .002
Angina pectoris 117 (37) 233 (48) .003 115 (37) 200 (46) .011
Routine prescription medications
ACE inhibitors 38 (12) 101 (21) .002 43 (14) 86 (20) .030
Beta-blockers 106 (34) 156 (32) .613 117 (38) 125 (29) .013
Calcium channel blockers 48 (15) 55 (11) .100 42 (14) 57 (13) .906
Diuretics 138 (44) 256 (52) .017 130 (42) 235 (54) .001
All BP-lowering drugs 217 (69) 349 (71) .439 211 (68) 315 (73) .130
Benzodiazepines 80 (25) 166 (34) .010 81 (26) 139 (32) .070
Antidepressants 38 (12) 98 (20) .003 29 (9) 98 (23) <.001
ASA 131 (42) 206 (42) .869 134 (43) 176 (41) .529
Neuroleptics 24 (8) 91 (19) <.001 24 (8) 75 (17) <.001
Warfarin 22 (7) 49 (10) .137 22 (7) 42 (10) .203
Analgesicsy 99 (31) 251 (51) <.001 86 (28) 231 (53) <.001
NSAIDs 27 (9) 37 (8) .611 20 (6) 40 (9) .162
Statins 26 (8) 18 (4) .005 21 (7) 20 (5) .212
No. of prescribed drugs 5.4  3.6 7.3  4.4 <.001 5.1  3.7 7.5  4.3 <.001
Assessments
Body mass index, n ¼ 776 25.9  4.1 24.8  4.6 .001 25.2  3.8 25.2  4.8 .88
MMSE score, range 0e30; n ¼ 790 25.1  3.8 18.2  8.6 <.001 25.1  4.2 18.8  8.2 <.001
Barthel ADL index, range 0e20; n ¼ 797 18.9  2.7 14.1  6.8 <.001 19.5  1.5 13.9  6.8 <.001
Gait speed,zm/s; n ¼ 609 0.58  0.21 0.46  0.20 <.001 0.68  0.16 0.35  0.10 <.001
Systolic BP 153.3  22.4 142.7  23.9 <.001 154.3  22.4 142.6  24.2 <.001
Diastolic BP, n ¼ 805 76.5  10.4 73.7  11.3 <.001 76.7  11.1 73.6  10.9 <.001
ACE, angiotensin-converting enzyme; ASA, acetylsalicylic acid; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; NSAIDs, nonsteroidal anti-
inﬂammatory drugs.
Data are presented as n (%) or mean  SD. Total number is presented after characteristics with some missing data.
*Comprises participants with gait speeds <0.5 m/s and those unable to complete the walking test due to habitual impairment of gait function.
yNSAIDs, opioids, and paracetamol.
zCalculated only for participants who completed the gait speed test.
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and 2 (HR 1.37, 95% CI 1.03e1.83), compared with the quartile of 75 to
80 mm Hg (eTable 1, eFigure 1A).
The association of BP with mortality differed among gait speed
subcohorts. In the slower-walking subcohort, patterns of association
were similar to those of the total sample (Table 3, Figure 2B, eTable 1,
eFigure 1B). In age- and sex-adjusted analysis of the faster-walking
subcohort, mortality risk was more than twice higher in partici-
pants with systolic BP of 125 mm Hg or lower than in those with
systolic BP of 126 to 139 mm Hg (HR 2.38, 95% CI 1.05e5.41). This
association did not reach statistical signiﬁcance in the fully adjusted
analysis (model 2); instead, mortality risk was more than twice
higher in participants with systolic BP of 165 mm Hg or higher (HR
2.13, 95% CI 1.01e4.49) and 140 to 149 mm Hg (HR 2.25, 95% CI
1.03e4.94) than in those with systolic BP of 126 to 139 mm Hg
(Table 3, Figure 2C). For diastolic BP, mortality was signiﬁcantly
higher in the highest quartile (>80 mm Hg) in models 1 (HR 1.65, 95%
CI 1.01e2.69) and 2 (HR 1.76, 95% CI 1.07e2.90) compared with thequartile of 75 to 80 mm Hg in the faster-walking subcohort (eTable 1,
eFigure 1C). In the age- and sex-adjusted analysis, interaction effects
between gait speed subcohort and BP in the association with mor-
tality were signiﬁcant for systolic BP (P ¼ .031), but not for diastolic
BP (P ¼ .283). Interaction effects were not signiﬁcant for systolic BP
(P ¼ .327) or diastolic BP (P ¼ .272) in the fully adjusted model.
Repeated analyses with the exclusion of data from participants
who died in the ﬁrst year of study inclusion produced essentially the
same results (data not shown).
Discussion
In this study of a representative sample of very old individuals,
low systolic and diastolic BP were signiﬁcantly associated with
increased mortality risk in initial age- and sex-adjusted analyses, but
not in analyses adjusted for all covariates, including previous disease.
Similar patterns of association were observed in the total sample and
the slower-walking subcohort (which also included habitually
Table 2
Mortality and Mean Gait Speed and BP Values by Age and Gait Speed Group
Group n Gait speed,* m/s P Systolic BP,
mm Hg
P Diastolic BP,
mm Hg
P Deceased
Within 5 y
P
Age group, y 806 490
85 348 0.57  0.21 (n ¼ 304) 152.3  23.0 76.5  10.5 151 (43.4)
90 260 0.50  0.21 (n ¼ 198) <.001 146.5  24.0 <.001 74.7  11.4 <.001 165 (63.5) <.001
95 198 0.43  0.19 (n ¼ 107) 137.8  22.4 71.9  11.1y 174 (87.9)
Gait speed group, m/s 745z 441
0.5 312 0.68  0.16 154.3  22.4 76.7  11.1 118 (37.8)
<0.5 297 0.35  0.10 <.001 146.9  23.5 <.001 74.8  10.6 <.001 199 (67.0) <.001
Habitually nonwalkingx 136 d 133.3  23.3 71.0  11.2y 124 (91.2)
Excluded nonwalking 61 d 138.7  18.1 73.6  10.5 49 (80.3)
Data are presented as n (%) or mean  SD. Differences between groups were examined using 1-way analyses of variance and Pearson c2 test.
*Calculated only for participants who completed the gait speed test.
yValue from 1 participant is missing.
zGait speed values were missing for 61 participants for reasons other than habitual impairment of gait function; these participants were excluded from gait speed analyses,
resulting in a gait speed subcohort of 745 participants.
xParticipants unable to complete the walking test due to habitual impairment of gait function.
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categories were signiﬁcantly and independently associated with
higher mortality risk, compared with intermediary systolic
(126e139 mm Hg) and diastolic (75e80 mm Hg) BP categories.
Similar to the ﬁndings of Odden et al18 in noninstitutionalized
people with a mean age of 74 years, our results indicate that greater
gait speed at usual pace is likely to also identify people in the multi-
morbid very old population, including care facility residents, with
increasedmortality risk due to high BP. Despite substantial differences
in disease burden, these results in the faster-walking subcohort are
analogous to those of the HYVET intervention study,13 in which
treatment of hypertension to a target systolic BP of 150mmHg reduced
mortality rates in comparatively healthy people aged 80 years or older.
In contrast, BP was not independently associated with mortality in the
slower-walking subcohort,which is also congruentwith theﬁndings of
Odden et al.18 The gait speed threshold of 0.5 m/s used in the present
study appears to adequately distinguish groups of very old peoplewith
and without increased mortality risk due to elevated systolic and
diastolic BP. These ﬁndings indicate that this thresholdwas suitable for
the present study population of very old individuals. Moreover, mean
gait speeds of thosewho lived and those who died within 5 years afterTable 3
Hazard Ratios for Death* for Systolic Blood Pressure in the Total Sample and According t
Systolic BP,
mm Hg
Total Sample P Gait Speed <
n HR (95% CI) n H
Model 1 806 433
125 1 1
126e139 0.70 (0.53e0.93) .014 0
140e149 0.63 (0.48e0.83) .001 0
150e164 0.59 (0.45e0.76) <.001 0
165 0.50 (0.38e0.66) <.001 0
Model 2 698z 399
125 1 1
126e139 0.87 (0.62e1.23) .439 0
140e149 1.07 (0.78e1.48) .668 0
150e164 0.97 (0.71e1.32) .828 0
165 1.03 (0.74e1.44) .860 0
Blood pressure reference category was chosen based on graphical interpretation of initi
Model 1 was adjusted for age and sex.
Model 2: In gait speed subcohorts adjusted for age, age  follow-up time, sex, congesti
pectoris, body mass index, and MMSE score; in total sample also adjusted for care facil
disease, hip fracture, angiotensin-converting enzyme inhibitors, calcium channel inhibito
drugs, and gait speed subcohort.
*Calculated using Cox proportional hazard regression models.
yComprises participants with gait speeds <0.5 m/s and those unable to complete the
zBecause model 2 included more covariates in the total sample than in the gait speed
subcohorts due to missing values.study inclusion fell on either side of this threshold (Table 1), further
supporting its relevance. The cutoff value of 0.8 m/s used by Odden
et al18 in a somewhat younger population may be difﬁcult to imple-
ment in those aged 85 years or older because few of these individuals
have gait speeds 0.8 m/s. Further population-based studies are
needed to investigate the role of gait speed in the development of other
complications of hypertension, such as stroke and dementia.
In line with several previous observations in very old in-
dividuals,8e10 BP was not found to be an independent risk factor for
mortality in the total sample of the present study. However, some
previous studies have found low BP to be independently associated
with higher mortality.4e6,11 Although resembling the present study in
other regards, these studies adjusted for fewer covariates, which may
account for the difference in results. Results from the total sample of
the present study suggest the existence of an inverse association
between BP and mortality that is independent of age and sex, but
dependent on other factors, such as disease. A similar association was
observed in the slower-walking subcohort (majority of the sample),
which may account in part for the association observed in the total
study sample. The slower-walking subcohort represents a portion of
the very old population with lower overall organ-system function,o Gait Speed Subcohort
0.5 m/sy P Gait Speed 0.5 m/s P
R (95% CI) n HR (95% CI)
312
2.38 (1.05e5.41) .038
.78 (0.56e1.08) .132 1
.70 (0.50e0.99) .043 2.14 (0.99e4.59) .052
.56 (0.40e0.77) <.001 1.98 (0.93e4.22) .079
.51 (0.35e0.72) <.001 1.92 (0.92e4.02) .084
311
1.83 (0.79e4.24) .158
.89 (0.62e1.28) .516 1
.94 (0.65e1.35) .727 2.25 (1.03e4.94) .042
.78 (0.55e1.11) .164 1.85 (0.86e3.99) .117
.85 (0.57e1.27) .428 2.13 (1.01e4.49) .048
al age- and sex-adjusted analyses in the total sample and in each gait speed group.
ve heart failure, atrial ﬁbrillation, myocardial infarction, cancer, depression, angina
ity residency, living alone, education, education  follow-up time, cerebrovascular
rs, diuretics, bensodiazepines, neuroleptics, warfarin, analgesics, statins, number of
walking test due to habitual impairment of gait function.
subcohorts, more participants were excluded in the total sample than in gait speed
Fig. 2. Survival curves based on Cox proportional hazard regression models of systolic blood pressure categories in the total sample (A, n ¼ 806) and by gait speed subcohort;
<0.5 m/s (B, n ¼ 433) and 0.5 m/s (C, n ¼ 312). The <0.5 m/s gait speed subcohort comprises participants with gait speeds <0.5 m/s and those unable to complete the walking test
due to habitual impairment of gait function. Model 1 was adjusted for age and sex. Model 2: In gait speed subcohorts adjusted for age, sex, congestive heart failure, atrial ﬁbrillation,
myocardial infarction, cancer, depression, angina pectoris, body mass index, and MMSE score; in total sample also adjusted for care facility residency, living alone, education,
cerebrovascular disease, hip fracture, angiotensin-converting enzyme inhibitors, calcium channel inhibitors, diuretics, bensodiazepines, neuroleptics, warfarin, analgesics, statins,
number of drugs, and gait speed subcohort.
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risk of adverse outcomes, which may be correlated more strongly
than hypertension with mortality. In many patients, these effects
could reﬂect imminent heart failure.27 In contrast, the faster-walking
subcohort had longer-than-average life expectancy and may have
been exposed to the pathologic effects of sustained hypertension,
such as death. As gait speed decreases with age in a group of very old
people, the association between hypertension and mortality may
cease to exist merely in comparison with the overall rising mortality
rate.
The present population-based study involved home visitation of
very old people, enabling participation of the frailest individuals and
care facility residents. Standardized face-to-face interviews, in com-
bination with data from medical records, provided extensive infor-
mation on comorbidities that was incorporated in the fully adjusted
regression model. The division of BP values into 4 or 5 categories al-
lowed for interpretation of nonlinear associations. Despite these
stengths, the present study has some limitations. Although mortality
data were reliable, information on cause of death was not collected.
The study was representative of people in the studied geographic area
aged 85, 90, and 95 years or older, and its results may not apply to a
general population of very old individuals. Furthermore, BP was
measured while participants were supine, which impedes comparison
with other studies. Because of the high prevalence of orthostatic
hypotension in very old people,28,29 the measurement of BP with
participants in a seated position might have produced a wider distri-
bution of BP values and lower mean values. Each participant’s BP was
measured onlyonce during ahomevisit,whichmay limit the reliability
of this measurement. However, data quality seemed to be acceptable
for group-level comparison, as BP was measured using a calibrated
manual sphygmomanometer according to a standardized procedure.
Finally, the statistical power of some subcohort analyses may have
been limited.
Conclusions
In conclusion, the association of BP with mortality differed in gait
speed subcohorts. High systolic and diastolic BP seem to be indepen-
dently associated with increasedmortality risk among very old people
with gait speeds of 0.5 m/s or faster. In slower-walking and habitually
nonwalking individuals, BP does not appear to be independently
associated with mortality. Low systolic and diastolic BP may be
markers of increased mortality risk in very old people with lower gait
speed, possibly secondary to failing health. Future studies should aim
to investigate the risks of other complications of hypertension in very
old people, with respect to gait speed. The gait speed threshold of
0.5 m/s may be clinically useful for the distinction of very old people
with and without increased mortality risk due to elevated systolic and
diastolic BP.
Supplementary Data
Supplementary Data related to this article can be found online at
http://dx.doi.org/10.1016/j.jamda.2014.09.004.
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